Xeris Biopharma Holdings, Inc. (LON: 0A8E)

Market Cap	398.24M
Revenue (ttm)	139.79M
Net Income (ttm)	-47.09M
Shares Out	n/a
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55
Average Volume	3,589
Open	3.340
Previous Close	3.339
Day's Range	3.300 - 3.340
52-Week Range	1.280 - 3.340
Beta	n/a
RSI	49.45
Earnings Date	Mar 6, 2025

About Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 377
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A8E

Financial Performance

In 2023, Xeris Biopharma Holdings's revenue was $163.91 million, an increase of 48.68% compared to the previous year's $110.25 million. Losses were -$62.26 million, -34.23% less than in 2022.

Financial numbers in USD